Psilocybin and Methylenedioxymethamphetamine (MDMA) for Post-traumatic Stress Disorder (PTSD) (PAM-VET)

This randomised, double-blind (first session) Phase I trial will compare a single experimental co-administration of MDMA followed 30 minutes later by psilocybin with an active-comparator co-administration in military Veterans with chronic PTSD (n=40).

Each participant will receive two dosing sessions (the second ~1.5 months after the first); the first dosing session is double-blind, the second is single-blind (participant-masked). Exact drug dosages are not disclosed in the registry fragment.